Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease
Top Cited Papers
- 1 July 2004
- journal article
- clinical trial
- Published by Elsevier in American Journal of Human Genetics
- Vol. 75 (1) , 65-74
- https://doi.org/10.1086/422366
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Improvement of Cardiac Function During Enzyme Replacement Therapy in Patients With Fabry DiseaseCirculation, 2003
- PR Interval and the Response to Enzyme-Replacement Therapy for Fabry's DiseaseNew England Journal of Medicine, 2003
- Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapyKidney International, 2002
- Natural History of Fabry Renal DiseaseMedicine, 2002
- Patients with Fabry disease on dialysis in the United StatesKidney International, 2002
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous malesJournal of Medical Genetics, 2001
- Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's DiseaseNew England Journal of Medicine, 2001
- A Phase 1/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety StudiesAmerican Journal of Human Genetics, 2001
- Quantitative Determination of Globotriaosylceramide by Immunodetection of Glycolipid-Bound Recombinant Verotoxin B SubunitAnalytical Biochemistry, 1999
- The short-form McGill pain questionnairePain, 1987